Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2,2- trimethylhydrazinium) propionate in mice: Inhibition of carnitine transport in kidney

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 1, 1999, Pages 93-102

  Kuwajima, Masamichi ^a   Harashima, Hideyoshi ^b   Hayashi, Miyuki ^b   Saori, Ise ^b   Masako, Sei ^b   Kang Mo, Lu ^b   Kiwada, Hiroshi ^b   Sugiyama, Yuichi ^b   Shima, Kenji ^b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; MILDRONATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG TRANSPORT; ENZYME ACTIVITY; FIBROBLAST; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; KIDNEY CLEARANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032940435     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. 2+ transport. J Biol Chem 254:12404-12410.
2. Akahira M, Hara A and Abiko Y (1997) Effect of MET-88, a γ-butyrobetaine hydroxylase inhibitor, on myocardial derangements induced by hydrogen peroxide in the isolated perfused rat heart. Fundam Clin Pharmacol 11:356-364.
3. Anderson RC, Balestra M, Bell PA, Deems RO, Fillers WS, Foley JE, Fraser JD, Mann WR, Rudin M and Villhauer EB (1995) Antidiabetic agents: A new class of reversible carnitine palmitoyltransferase I inhibitors. J Med Chem 38:3448-3450.
4. Aoyagi T, Sugiura S, Eto Y, Yonekura K, Matsumoto A, Yokoyama I, Kobayakawa N, Omata M, Kirimoto T, Hayashi Y and Momomura S (1997) Inhibition of carnitine synthesis protects against left ventricular dysfunction in rats with myocardial ischemia. J Cardiovasc Pharmacol 30:468-474.
5. Bahl J, Navin T, Manian AA and Bressler R (1981) Carnitine transport in isolated adult rat heart myocytes and the effect of 7,8-di OH chlorpromazine. Circ Res 48:378-385.
6. Borum PR (1983) Carnitine. Annu Rev Nutr 3:233-259.
7. Bremer J (1983) Carnitine - metabolism and functions. Physiol Rev 63:1420-1480.
8. Christiansen RZ and Bremer J (1976) Active transport of butyrobetaine and carnitine into isolated liver cells. Biochim Biophys Acta 448:562-577.
9. Corr PB, Gross RW and Sobel BE (1984) Amphipathic metabolites and membrane dysfunction in ischemic myocardium. Circ Res 55:135-154.
10. Dhalla NS, Elimban V and Rupp H (1992) Paradoxical role of lipid metabolism in heart function and dysfunction. Mol Cell Biochem 116:3-9.
11. Dhar PK, Grupp IL, Schwartz A, Grupp G and Matlib MA (1996) Reduction of carnitine content by inhibition of its biosynthesis results in protection of isolated guinea pig hearts against hypoxic damage. J Cardiovasc Pharmacol Therapeut 1:235-242.
12. Evans AM, Mancinelli A and Longo A (1997) Excretion and metabolism of propionyl-L-carnitine in the isolated perfused rat kidney. J Pharmacol Exp Ther 281:1071-1076.
13. Horiuchi M, Kobayashi K, Yamaguchi S, Shimizu N, Koizumi T, Nikaido H, Hayakawa J, Kuwajima M and Saheki T (1994) Primary defect of juvenile visceral steatosis (jvs) mouse with systemic carnitine deficiency is probably in renal carnitine transport system. Biochim Biophys Acta 1226:25-30.
14. Huth PJ and Shug AL (1980) Properties of carnitine transport in rat kidney cortex slices. Biochim Biophys Acta 602:621-634.
15. Kaido M, Fujimura H, Ono A, Toyooka K, Yoshikawa H, Nishimura T, Ozaki K, Narama I, Kuwajima M (1997) Mitochondrial abnormalities in a murine model of primary carnitine deficiency. Eur Neurol 38:302-309.
16. Kaneko H and Goshima K (1982) Selective killing of fibroblast-like cells in cultures of mouse heart cells by treatment with a Ca ionophore, A23187. Exp Cell Res 142:407-416.
17. Kirimoto T, Nobori K, Asaka N, Muranaka Y, Tajima K and Miyake H (1996) Beneficial effect of MET-88, a γ-butyrobetaine hydroxylase inhibitor, on energy metabolism in ischemic dog hearts. Arch Int Pharmacodyn Thèr 331:163-178.
18. Kuwajima M, Kono N, Horiuchi M, Imamura Y, Ono A, Inui Y, Kawata S, Koizumi T, Hayakawa J, Saheki T and Tarui S (1991) Animal model of systemic carnitine deficiency: Analysis in C3H-H-2° strain of mouse associated with juvenile visceral steatosis. Biochem Biophys Res Commun 174:1090-1094.
19. Kuwajima M, Lu K-M, Harashima H, Ono A, Sato I, Mizuno A, Murakami T, Nakajima H, Miyagawa J, Namba M, Hanafusa J, Hayakawa J, Matsuzawa Y and Shima K (1996) Carnitine transport defect in fibroblasts of juvenile visceral steatosis (JVS) mouse. Biochem Biophys Res Commun 223:283-287.
20. Kuwajima M, Lu K-M, Sei M, Ono A, Hayashi M, Ishiguro K, Ozaki K, Hotta K, Okita K, Murakami T, Miyagawa J, Narama I, Nikaido H, Hayakawa J, Nakajima H, Namba M, Hanafusa T, Matsuzawa Y and Shima K (1998) Characteristics of cardiac hypertrophy in the juvenile visceral steatosis mouse with systemic carnitine deficiency. J Mol Cell Cardiol 30:773-781.
21. Lopaschuk GD, Wall SR, Olley PM and Davies NJ (1988) Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid - induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 63:1036-1043.
22. Mancinelli A, Longo A, Shanahan K and Evans AM (1995) Disposition of L-carnitine and acetyl-L-carnitine in the isolated perfused rat kidney. J Pharmacol Exp Ther 274:1122-1128.
23. McGarry JD and Foster DW (1985) Free and esterified carnitine. Radiometric method, in Methods of Enzymatic Analysis (Bergmeyer HU ed) pp 474-481, Academic Press, New York.
24. McGarry JD, Mills SE, Long CS and Foster DW (1983) Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Biochem J 214:21-28.
25. Miyagawa J, Kuwajima M, Hanafusa T, Ozaki K, Fujimura H, Ono A, Uenaka R, Narama I, Oue T, Yamamoto K, Kaidoh M, Nikaido H, Hayakawa J, Horiuchi M, Saheki T and Matsuzawa Y (1995) Mitochondrial abnormalities of muscle tissue in mice with juvenile visceral steatosis associated with systemic carnitine deficiency. Virchows Arch 426:271-279.
26. Narama I, Ozaki K, Matsuura T, Ono A, Sei M, Shima K and Kuwajima M (1997) Heterogeneity of histopathologic features in the congenitally carnitine-deficient juvenile visceral steatosis (JVS) mouse. Biomed Res 18:247-255.
27. Rebouche CJ and Mack DL (1984) Sodium gradient-stimulated transport of L-carnitine into renal brush border membrane vesicles: Kinetics, specificity, and regulation by dietary carnitine. Arch Biochem Biophys 235:393-402.
28. Rozen R, Scriver CR and Mohyuddin F (1983) Hypertaurinuria in the C57BL/6J mouse: Altered transport at the renal basolateral membrane. Am J Physiol 244: F150-F155.
29. Sahartova O, Shatz V and Kalvins I (1993) HPLC analysis of mildronate and its analogues in plasma. J Pharm Biomed Anal 11:1045-1047.
30. Simkhovich BZ, Shutenko ZV, Meirena DV, Khagi KB, Mezapuke RJ, Molodchina TN, Kalvins IJ and Lukevics E (1988) 3-(2,2,2-trimethylhydrazinium) propionate (THP) - a novel γ-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochem Pharmacol 37:195-202.
31. Stieger B, O'Neill B and Krähenbühl S (1995) Characterization of L-carnitine transport by rat kidney brush-border-membrane vesicles. Biochem J 309:643-647.
32. Takahashi M, Ueda S, Misaki H, Sugiyama N, Matsumoto K, Matsuo N and Murao S (1994) Carnitine determination by an enzymatic cycling method with carnitine dehydrogenase. Clin Chem 40:817-821.
33. Tipping PG, Kitching AR, Huang XR, Mutch DA and Holdsworth SR (1997) Immune modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis. Eur J Immunol 27:530-537.
34. Woeltje KF, Kuwajima M, Foster DW and McGarry JD (1987) Characterization of the mitochondrial carnitine palmitoyltransferase enzyme system. II. Use of detergents andantibodies. J Biol Chem 262:9822-9827.
35. Yamaoka K, Tanigawara Y, Nakagawa T and Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharm Dyn 4:879-885.